ATP-sensitive potassium channels (K ATP ) channels are widely distributed in various tissues, including pancreatic beta cells, muscle tissue and brain tissue. K ATP channels play an important role in cardioprotection in physiological/pathological situations.
| INTRODUCTION
Arrhythmia is a leading cause of mortality and morbidity in cardiovascular diseases. Several ion channels in cardiomyocytes shape action potentials, trigger electrophysiological activities, and excitation-contraction coupling (ECC), and finally, induce cardiac contraction and blood pumping within the circulatory system. Abnormal ion channels may affect cardiac function.
The ATP-sensitive potassium (K ATP ) channel was first identified by Noma in cardiomyocytes treated with hypoxia using the patch clamp technique in 1983. 1 K ATP channels are characterized by channel inhibition because of an increase in the intracellular ATP concentration and stimulation because of an increase in the intracellular MgADP concentration. [2] [3] [4] Cumulative evidence has indicated that K ATP channels, which are ATP-sensitive potassium channels, are widely distributed in various tissues, including pancreatic beta cells, muscle tissue, and brain tissue, and play an important role in cardioprotection in physiological and/or pathological states. Particularly, under pathophysiological conditions, K ATP channels play a critical protective role by regulating cardiac repolarization. Activation of K ATP channels decreases ischaemia/ reperfusion injury, protects cardiomyocytes during heart failure, and reduces the occurrence of arrhythmias.
K ATP channels couple the cellular metabolic state to the membrane potential. K ATP channels play a critical role in various cellular functions, including hormone secretion and regulation of muscle excitability. K ATP channels are also the target of endogenous vasoactive substances, such as nitric oxide (NO), reactive oxygen species (ROS), and hydrogen sulphide (H 2 S). 5, 6 The protective mechanisms of Table 2 ). The Kir6.2 subunit has more intrinsic sensitivity to cellular metabolic disorders than the Kir6.1 subunit. 16 In addition, the composition of the mitochondrial K ATP (mitoK ATP ) channels is still unclear, although some literature suggests that Kir6.1 may be a functionally important part of mitoK ATP channels in native heart cells. 17 
| CARDIAC DISEASES
The opening and closing of K ATP channels are regulated by various signalling molecules, including membrane phosphoinositides, the intracellular ATP concentration, and MgADP. 18 Small signalling molecules, such as NO, H 2 S, and ROS, also play critical roles in protecting the cardiovascular system by regulating K ATP channels. 
| Cardiomyopathy
The opening of K ATP channels protects cardiac muscle cells against hyperglycaemia-induced damage and inflammation by inhibiting the ROS-activated TLR4-necroptosis pathway, which may be an important underlying mechanism of ROS in diabetic cardiomyopathy.
These results indicated the cardio-protective effects again injury induced by ROS in a KATP channels-dependent manner. 
| Cardiac arrhythmias
Cardiac K ATP channels have emerged as crucial controllers of heart failure and ischaemia-related cardiac arrhythmias and have been suggested to be responsible for cardioprotection by decreasing repolarization dispersion and promoting action potential shortening. [25] [26] [27] In cardiomyocytes, the ability of the mitochondrial network, which restores energy production and limits necrotic and apoptotic cell death, is a key determinant of survival after ischaemia-reperfusion (IR). Mitochondrial function is a major factor in arrhythmogenesis during IR. Mitochondrial uncoupling can alter cellular electrical excitability and increase the propensity for reentry through opening of sarcolemmal K ATP channels. Mitochondrial inner membrane potential (ΔΨm) is an essential component in the process of energy storage. ΔΨm instability or oscillation induced by ROS led to cardiac arrhythmia. This mechanism is necessary to increase the dispersion of refractoriness, slow the conduction velocity, and create a regional excitation block. 28 Recent data have shown that mutations of K ATP channels in myocardial cells can directly result in arrhythmias. The E23K variant of KCNJ11, identified in patients with type 2 diabetes, 29 results in the frequent opening of K ATP channels, which is associated with a greater left ventricular size with hypertension. 30 These mutations, in turn, increases the occurrence of ventricular arrhythmias (VA) in dilated cardiomyopathy patients. Moreover, a KCNJ8 mutation was also found to be associated with atrial fibrillation (AF), and K ATP channel currents were found to be decreased during chronic human AF. 31 Feng et al 32 reported that by over-expressing the E23K variant, ventricular electrophysiological instability was increased when impaired by acute ischaemia. However, low-doses of diazoxide, a K ATP channel opener, improved hypoglycaemia-related complications in patients with type 2 diabetes mellitus (T2DM), resulting in rapid and heterogeneous APD shortening to promote reentrant ventricular tachyarrhythmias during ischaemia. 33 
| Mutations in human disease
Patients with Cantu syndrome, which is caused by gain-of-function (GOF) mutations in genes encoding Kir6.1 and SUR2, have enlarged hearts with an increased ejection fraction and increased contractility.
Mice with cardiac-specific Kir6.1 GOF subunit expression show left ventricular dilation and increased basal L-type Ca 2+ currents, which results in phosphorylation of the pore-forming α 1 subunit of the cardiac voltage-gated calcium channel Cav1.2 at Ser1928 relative to that in WT mice treated with isoproterenol. 34 This result suggests that increasing protein kinase activity may act as a potential connection between increased K ATP current and cardioprotection.
| DRUG THERAPY AND PERSPECTIVE
K ATP channels, a major drug target for the treatment of T2DM, are crucial in the regulation of heart injury and vascular smooth muscle tone. K ATP channels are also important since the therapeutic agents that target K ATP channels can also treat cardiovascular diseases. New effects correlated with K ATP channels have recently been identified that were previously undetected. For example, the volatile anaesthetic isoflurane preserves the normalization of human K ATP channel activity in human arteries exposed to oxidative stress caused by high glucose. 35 Isoquercitrin induces vasodilation in resistance arteries, an effect that is mediated by the opening of K ATP channels and endothelial NO production. Isosteviol sodium may increase the activation rate of sarcK ATP channels induced by pinacidil and potentiate the diazoxide-elicited oxidation of flavoproteins in mitochondria. 39 The new antihypertensive drug iptakalim activates K ATP channels in the endothelial cells of resistance blood vessels, a mechanism that is dependent on ATP hydrolysis and specific ATP ligands. The functions of endothelial K ATP channels in resistance blood vessels can be changed by the exposure to the high shear stress caused by hypertension. 40 Sulfonylurea induces the release of insulin by inhibiting the K ATP channels that are present in pancreatic beta cells. Under high glucose conditions, glucose promotes the synthesis of intracellular ATP, which blocks K ATP channels and prevents K + efflux, leading to membrane depolarization and the opening of Ca 2+ channels, allowing an influx of calcium and release of insulin. 41, 42 Although efforts to reduce cardiovascular mortality in patients with diabetes mellitus should focus on improving glycaemic control, there is controversy as to whether the use of sulfonylurea increases the susceptibility of the myocardium to ischaemic insult, in light of the functional mechanisms of sulfonylurea drugs, which act through inhibition of the K ATP channels present in both pancreatic beta cells and cardiomyocytes. [25] [26] [27] 43, 44 Cardiac K ATP channels inhibited by sulfonylurea drugs may be harmful to the ischaemic myocardium because of a disturbed K ATP channel dependent response in the ischaemic precondition response. 26 Further research is needed to develop a "selective" drug that targets pancreatic KATP channels without affecting cardiac channels.
It is clear that K ATP channels play a significant role in the protection against cardiovascular diseases. In the literature, there is a considerable volume of information available regarding the mechanism of the protective role of K ATP channels under different pathophysiological conditions, such as I/R injury, heart failure, cardiac arrhythmias, and atherosclerosis. However, studies characterizing K ATP channels in targeted therapy of patients as well as the research and development of efficacious therapies are sparse, and further studies should investigate the potential mechanisms of K ATP channels in cardiovascular diseases.
